We strictly follow medical-grade protocols, using only sterile, approved methods
The FDA has evaluated BPC-157 as a bulk drug substance for compounding and raised questions about its safety data
Limited clinical validation: Despite decades of research interest, DSIP has not progressed into wide-scale clinical adoption, which raises questions about consistency and reproducibility of effects
In recent years, 5Amino1MQ Peptide (abbreviated as 5Amino1MQ), a highly selective smallmolecule peptide inhibitor targeting nicotinamide Nmethyltransferase (NNMT), has exhibited broad application prospects and become a research hotspot in obesity and adipose tissue research due to its unique mechanism, favorable targeting ability, and safety
Draft guidance for industry
This is harder to quantify but worth noting